drugset / Trial / NCT00209469

Network Osteoporosis Study

NCT00209469

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is evaluating the use of the drug alendronate in preventing or reversing bone loss in children and adolescents receiving steroid medications.

Timeline

Start
2002-07
Primary completion
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule

Indications